Cells resistant to TMZ showed elevated BRD4 levels. When treated with the PROTAC alone, these cells experienced a dose-dependent reduction in BRD4. Combining the PROTAC with TMZ lowered the amount of ...

BRD4 or VHL NanoLuc fusions were individually expressed in HEK293 cells. Intracellular engagement was quantified using TE BRD Tracer 02 or VHL tracer, following a 3-hr equilibration (Figures 3A & 3B).

Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...

Overcome Roadblocks to PROTAC Characterization. How To Guide . Last Updated: September 4, 2023 (+ more) Published: August 4, 2023 Credit: Nanotemper. Proteolysis-targeting chimeras (PROTACs) are ...

A PROTAC COMPOUND developed at the University of Dundee is being made available free of charge by the pharmaceutical company Boehringer Ingelheim through their scientific crowdsourcing platform ...

DeepCure to Present First Ex Vivo Rheumatoid Arthritis Patient Data for Selective BRD4 (BD2) Inhibitor DC-9476 at ACR Convergence 2024 October 24, 2024 08:00 AM Eastern Daylight Time ...

“Our selective BRD4 (BD2) inhibitor, DC-9476, demonstrates a potentially new strategy to treat MAS by directly inhibiting macrophage activation,” said Kfir Schreiber, CEO & Co-Founder of DeepCure.

This guide highlights how an innovative, plate-based, and automation-ready affinity screening solution helps you overcome roadblocks in your PROTAC characterization projects.